Gareth Rivalland

549 total citations
26 papers, 248 citations indexed

About

Gareth Rivalland is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Gareth Rivalland has authored 26 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 6 papers in Immunology. Recurrent topics in Gareth Rivalland's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Research and Treatments (5 papers). Gareth Rivalland is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Research and Treatments (5 papers). Gareth Rivalland collaborates with scholars based in Australia, New Zealand and United States. Gareth Rivalland's co-authors include Thomas John, Paul Mitchell, Bruce E. Loveland, Marzena Walkiewicz, Paul Mitchell, Fred R. Hirsch, Simon J Mitchell, Hui Yu, Gavin Wright and Bibhusal Thapa and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

Gareth Rivalland

24 papers receiving 247 citations

Peers

Gareth Rivalland
Ahmed Bilal Khalid United States
Qian Miao China
Jane Straus United States
Serena Zanotta Italy
Shahla Bari United States
Lu Pei China
Maria Lucia Iacovino Italy
Guangming Tian China
Divya Nagarajan United Kingdom
Ahmed Bilal Khalid United States
Gareth Rivalland
Citations per year, relative to Gareth Rivalland Gareth Rivalland (= 1×) peers Ahmed Bilal Khalid

Countries citing papers authored by Gareth Rivalland

Since Specialization
Citations

This map shows the geographic impact of Gareth Rivalland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gareth Rivalland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gareth Rivalland more than expected).

Fields of papers citing papers by Gareth Rivalland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gareth Rivalland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gareth Rivalland. The network helps show where Gareth Rivalland may publish in the future.

Co-authorship network of co-authors of Gareth Rivalland

This figure shows the co-authorship network connecting the top 25 collaborators of Gareth Rivalland. A scholar is included among the top collaborators of Gareth Rivalland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gareth Rivalland. Gareth Rivalland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Eggermont, Alexander M.M., Paolo A. Ascierto, Nikhil I. Khushalani, et al.. (2022). PIVOT-12: a Phase III Study of Adjuvant Bempegaldesleukin Plus Nivolumab in Resected Stage III/IV Melanoma at High Risk for Recurrence. Future Oncology. 18(8). 903–913. 8 indexed citations
4.
Yu, Hui, Leonid Churilov, Gareth Rivalland, et al.. (2021). NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. Clinical Lung Cancer. 23(2). e90–e98. 6 indexed citations
5.
6.
Leal, José Luis, Marcin Szaumkessel, Trishe Leong, et al.. (2020). NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. Lung Cancer. 146. 154–159. 24 indexed citations
7.
Brockwell, Natasha K., Muhammad Alamgeer, Beena Kumar, et al.. (2020). Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. Translational Lung Cancer Research. 9(3). 639–645. 16 indexed citations
8.
Rivalland, Gareth, et al.. (2020). Osimertinib in NSCLC: Real-World Data From New Zealand. JTO Clinical and Research Reports. 1(2). 100022–100022. 4 indexed citations
9.
Rivalland, Gareth, Paul Mitchell, Carmel Murone, et al.. (2019). Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. Translational Lung Cancer Research. 8(2). 167–175. 6 indexed citations
10.
Arulananda, Surein, Hongdo Do, Gareth Rivalland, et al.. (2019). Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. Journal of Thoracic Disease. 11(5). 1756–1764. 10 indexed citations
11.
Thapa, Bibhusal, Gareth Rivalland, Carmel Murone, et al.. (2018). OA08.05 Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) -Defining the Hot, the Warm and the Cold Tumours.. Journal of Thoracic Oncology. 13(10). S339–S339. 1 indexed citations
12.
Ren, Shengxiang, Hui Yu, Christopher J. Rivard, et al.. (2018). The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. Lung Cancer. 125. 115–120. 38 indexed citations
13.
Mauti, Laetitia, Gareth Rivalland, Dirk Klingbiel, et al.. (2017). Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH). Annals of Oncology. 28. xi8–xi8. 1 indexed citations
14.
Rivalland, Gareth, Andrew M. Scott, & Thomas John. (2017). Standard of care in immunotherapy trials: Challenges and considerations. Human Vaccines & Immunotherapeutics. 13(9). 2164–2178. 3 indexed citations
15.
Thapa, Bibhusal, Marzena Walkiewicz, Gareth Rivalland, et al.. (2017). Immune microenvironment in mesothelioma: Looking beyond PD-L1.. Journal of Clinical Oncology. 35(15_suppl). 8515–8515. 5 indexed citations
16.
Do, Hongdo, Daniel Cameron, Ramyar Molania, et al.. (2016). Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA. Advances in experimental medicine and biology. 924. 139–146. 5 indexed citations
17.
Rivalland, Gareth, Malaka Ameratunga, Marzena Walkiewicz, et al.. (2016). Programmed Death–Ligand 1 (PD-L1) immumohistochemistry in NSCLC: Comparison and correlation between two antibodies.. Journal of Clinical Oncology. 34(15_suppl). e20036–e20036. 3 indexed citations
18.
Rivalland, Gareth, Bruce E. Loveland, & Paul Mitchell. (2015). Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Expert Opinion on Biological Therapy. 15(12). 1773–1787. 36 indexed citations
19.
Kvizhinadze, Giorgi, et al.. (2014). Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand. PharmacoEconomics. 32(7). 707–724. 3 indexed citations
20.
Rivalland, Gareth, et al.. (2010). Pulmonary Barotrauma and Cerebral Arterial Gas Embolism During Hyperbaric Oxygen Therapy. Aviation Space and Environmental Medicine. 81(9). 888–890. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ahmed Bilal Khalid Breakdown of academic impact, for papers by Qian Miao Breakdown of academic impact, for papers by Jane Straus Breakdown of academic impact, for papers by Serena Zanotta Breakdown of academic impact, for papers by Shahla Bari Breakdown of academic impact, for papers by Lu Pei Breakdown of academic impact, for papers by Maria Lucia Iacovino Breakdown of academic impact, for papers by Guangming Tian Breakdown of academic impact, for papers by Divya Nagarajan
Rankless by CCL
2026